168 related articles for article (PubMed ID: 8869094)
21. [Level of CA 15-3 antigen--a prognostic factor in patients with breast cancer?].
Wojtacki J; Dziewulska-Bokiniec A; Kowalski DM; Zółtowska A; Ciesielski D; Suszko M
Przegl Lek; 1996; 53(11):788-92. PubMed ID: 9173440
[TBL] [Abstract][Full Text] [Related]
22. [Progressive increase of serum circulating immune complexes and its significance in patients during the progression from chronic hepatitis B to hepatocellular carcinoma].
Du J; Tian P; Chen TY; Wu JX; Wang JB; Wei Y; Wang LM; Liu LG; Ji WS; Qu CF
Zhonghua Zhong Liu Za Zhi; 2011 Dec; 33(12):905-10. PubMed ID: 22340099
[TBL] [Abstract][Full Text] [Related]
23. Clinical utility and monitoring of breast cancer by circulating immune complexes.
Dass TK; Aziz M; Rattan A; Tyagi SP
Indian J Pathol Microbiol; 1992 Oct; 35(4):298-307. PubMed ID: 1344219
[TBL] [Abstract][Full Text] [Related]
24. Circulating levels and clinical implications of epithelial membrane antigen and cytokeratin-1 in women with breast cancer: can their ratio improve the results?
Attallah AM; El-Far M; Omran MM; Abdallah SO; El-Desouky MA; El-Dosoky I; Abdelrazek MA; Attallah AA; Elweresh MA; Abdel Hameed GE; Shawki HA; Salama KS; El-Waseef AM
Tumour Biol; 2014 Nov; 35(11):10737-45. PubMed ID: 25073515
[TBL] [Abstract][Full Text] [Related]
25. Prognostic significance of circulating immune complexes in cancer patients.
Dass TK; Aziz M; Rattan A
Jpn J Cancer Res; 1991 Nov; 82(11):1284-91. PubMed ID: 1752784
[TBL] [Abstract][Full Text] [Related]
26. Diagnostic relevance of a novel multiplex immunoassay panel in breast cancer.
Hermann N; Dressen K; Schroeder L; Debald M; Schildberg FA; Walgenbach-Bruenagel G; Hettwer K; Uhlig S; Kuhn W; Hartmann G; Holdenrieder S
Tumour Biol; 2017 Jun; 39(6):1010428317711381. PubMed ID: 28618926
[TBL] [Abstract][Full Text] [Related]
27. Immunosuppressive acidic protein serum levels in breast cancer patients in a reference to CA 15-3 levels.
Cohen AD; Shoenfeld Y; Gopas J; Cohen Y
Breast Cancer Res Treat; 1994; 30(2):197-200. PubMed ID: 7949217
[TBL] [Abstract][Full Text] [Related]
28. Prognostic significance of circulating immune complexes in a long-term follow-up of breast cancer patients.
Iaffaioli RV; Bianchin A; Ruggiero G; Pirozzi G; Ungaro A; Totaro G; Gallo C; De Placido S; Pagliarulo C; Bianco AR
Oncology; 1988; 45(5):337-43. PubMed ID: 3412739
[TBL] [Abstract][Full Text] [Related]
29. Expression and significance of ER, PR, VEGF, CA15-3, CA125 and CEA in judging the prognosis of breast cancer.
Zhang SJ; Hu Y; Qian HL; Jiao SC; Liu ZF; Tao HT; Han L
Asian Pac J Cancer Prev; 2013; 14(6):3937-40. PubMed ID: 23886210
[TBL] [Abstract][Full Text] [Related]
30. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA).
Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S
Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221
[TBL] [Abstract][Full Text] [Related]
31. [Clinical significance of circulating immune complexes in patients with metastatic breast cancer].
Krieger G; Kehl A; Bause I; Kneba M; Nagel GA
Klin Wochenschr; 1982 Dec; 60(23):1465-72. PubMed ID: 7154620
[TBL] [Abstract][Full Text] [Related]
32. Detection of circulating mammary mucin (Muc1) and MUC1 immune complexes (Muc1-CIC) in healthy women.
Croce MV; Isla-Larrain MT; Price MR; Segal-Eiras A
Int J Biol Markers; 2001; 16(2):112-20. PubMed ID: 11471893
[TBL] [Abstract][Full Text] [Related]
33. Humoral immunity against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic, and colon cancer patients.
Kotera Y; Fontenot JD; Pecher G; Metzgar RS; Finn OJ
Cancer Res; 1994 Jun; 54(11):2856-60. PubMed ID: 7514493
[TBL] [Abstract][Full Text] [Related]
34. HER-2 gene amplification, serum nucleosomes, CEA and CA15.3 tumor markers in breast cancer patients.
Zeiwar MM; Zaki SM; Mohammad LA; Zidan AA; El Nagar MR
Egypt J Immunol; 2007; 14(2):29-41. PubMed ID: 20306655
[TBL] [Abstract][Full Text] [Related]
35. Follow-up of patients with localized breast cancer and first indicators of advanced breast cancer recurrence: A retrospective study.
Viot J; Bachour M; Meurisse A; Pivot X; Fiteni F
Breast; 2017 Aug; 34():53-57. PubMed ID: 28505557
[TBL] [Abstract][Full Text] [Related]
36. Significance of breast carcinoma-associated antigens as a monitor of tumor burden: characterization by monoclonal antibodies.
Salinas FA; Wee KH; Ceriani RL
Cancer Res; 1987 Feb; 47(3):907-13. PubMed ID: 3802085
[TBL] [Abstract][Full Text] [Related]
37. [Plasminogen activator inhibitor 1 and prognosis in breast carcinoma].
Mayerhofer K; Stolzlechner J; Yildiz S; Haider K; Heinzl H; Jakesz R; Pecherstorfer M; Rosen H; Sevelda P; Zeillinger R; Speiser P
Geburtshilfe Frauenheilkd; 1996 Jan; 56(1):23-7. PubMed ID: 8852782
[TBL] [Abstract][Full Text] [Related]
38. A prospective study of circulating immune complexes in patients with breast cancer.
Bukh A; Aguado MT; Krarup N; Poulsen HS; Nordentoft AM; Møller NP
Int J Cancer; 1988 Mar; 41(3):364-70. PubMed ID: 3257943
[TBL] [Abstract][Full Text] [Related]
39. The use of carbohydrate antigen (CA) 15-3 as a tumor marker in detecting breast cancer.
Agyei Frempong MT; Darko E; Addai BW
Pak J Biol Sci; 2008 Aug; 11(15):1945-8. PubMed ID: 18983038
[TBL] [Abstract][Full Text] [Related]
40. Preoperative values of CA 15-3 and CEA as prognostic factors in breast cancer: a multivariate analysis.
Cañizares F; Sola J; Pérez M; Tovar I; De Las Heras M; Salinas J; Peñafiel R; Martínez P
Tumour Biol; 2001; 22(5):273-81. PubMed ID: 11553856
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
